Stockreport

ASLAN Pharmaceuticals Announces Study Results from Phase 2 Study of Varlitinib in First-line Gastric Cancer

ASLAN Pharmaceuticals Limited - American Depositary Shares  (ASLN) 
US:NASDAQ Investor Relations: ir.aslanpharma.com
PDF SINGAPORE, Jan. 14, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both [Read more]